Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

SWOG S1815 Shows Need for Subgroup-Specific Triplet Chemotherapy Assessment in Biliary Tract Cancer

March 5th 2025

Rachna Shroff, MD, MS, FASCO, discusses the potential role for nab-paclitaxel plus gemcitabine and cisplatin in select patients with biliary tract cancers.

Tivozanib Preserves QOL From Baseline to Week 24 in ICI-Pretreated RCC

March 4th 2025

Katy Beckermann, MD, PhD, discusses key findings from a PRO analysis of tivozanib/nivolumab vs tivozanib alone in ICI-pretreated RCC.

Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS

March 4th 2025

Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.

FDA Approves First-Line Tislelizumab Plus Chemotherapy for Unresectable or Metastatic ESCC

March 4th 2025

The FDA has approved tislelizumab-jsgr plus chemotherapy for frontline use in adult patients with advanced esophageal squamous cell carcinoma and PD-L1 expression.

Dr Lee on the Rationale for Using Integrative Medicine in Patients With GI Cancers

March 4th 2025

Richard T. Lee, MD, discusses research showing the benefits of acupuncture, ginger, and ginseng for improving symptoms in patients with GI cancers.

Dr Vlachou on Primary Tumor Responses With Enfortumab Vedotin in Upper Tract Urothelial Cancer

March 4th 2025

Evangelia Vlachou, MD, discusses response rates with enfortumab vedotin alone or with pembrolizumab in patients with upper tract urothelial cancer.

FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD

March 3rd 2025

Marwan G. Fakih, MD discusses the significance of this approval, key findings from the pivotal CodeBreaK 300 trial, and how this combination fits into the current KRAS G12C–mutated mCRC treatment paradigm.

Disparities in RCC Trial Access Illuminate the Need for Global Scientific Collaboration

March 3rd 2025

Regina Barragan-Carrillo, MD, discusses a study of RCC clinical trial availability and barriers to opening RCC clinical trials in lower-income countries.

Revisit Every OncLive On Air Episode From February 2025

March 3rd 2025

Read a recap of the episodes of OncLive On Air that aired in February 2025.

Dr Chiorean on Encorafenib Plus Cetuximab for BRAF V600E–Mutated mCRC

February 28th 2025

E. Gabriela Chiorean, MD, FASCO, discusses the FDA approval of encorafenib plus cetuximab and chemotherapy for patients with BRAF V600E–mutated mCRC.

Dr Li on the Casdozokitug/Atezolizumab/Bevacizumab in Unresectable HCC

February 28th 2025

Daneng Li, MD, discusses a trial evaluating casdozokitug plus atezolizumab and bevacizumab in unresectable, locally advanced or metastatic HCC.

Dr Smaglo on Selecting Between Frontline Chemotherapy Regimens for Pancreatic Cancer

February 28th 2025

Brandon G. Smaglo, MD, FACP, discusses considerations for choosing between frontline chemotherapy-based regimens for patients with pancreatic cancer.

Immunotherapy Combinations Reign Supreme in Upfront Melanoma Management

February 28th 2025

Teresa Petrella, MD, MHSc, FRCPC, discusses long-term data that inform the sequencing of immunotherapy and targeted therapies for frontline melanoma.

Dr Winer on the Efficacy of Emavusertib in AML With FLT3 and Spliceosome Factor Mutations

February 28th 2025

Eric S. Winer, MD, discusses the efficacy of emavusertib in patients with relapsed/refractory AML harboring FLT3 and/or spliceosome factor mutations.

FDA Approval Insights: T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

February 27th 2025

Dr Bardia discusses the FDA approval of T-DXd for patients with unresectable or metastatic, hormone receptor–positive, HER2-low/-ultralow breast cancer.

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

February 26th 2025

Drs Park, Grivas, and Raychaudhuri discuss a trial of neoadjuvant aMVAC plus pembrolizumab in patients with non-urothelial muscle-invasive bladder cancer.

Orca-Q Delivers Early Evidence of GVHD Risk Mitigation in Hematologic Malignancies

February 26th 2025

Amandeep Salhotra, MD, discusses data that have demonstrated the anti-GVHD activity of post-transplant Orca-Q in patients with hematologic malignancies.

Dr Daneshmand on Using TAR-200 to Address Unmet Needs in BCG-Unresponsive NMIBC

February 25th 2025

Sia Daneshmand MD, discusses how the intravesical therapy TAR-200 could address unmet needs for patients with high-risk, BCG-unresponsive NMIBC with CIS.

Ibrutinib/Venetoclax/Obinutuzumab Controls Disease at 5 Years in Newly Diagnosed MCL

February 25th 2025

At 5 years of follow-up, sustained disease control was demonstrated with ibrutinib plus venetoclax and obinutuzumab in patients with newly diagnosed MCL.

Triplet Chemo Trial Raises Importance of Accurately Defined Subgroups in Biliary Tract Cancer Research: With Rachna Shroff, MD, MS, FASCO

February 24th 2025

Dr Shroff discusses the SWOG S1815 trial of nab-paclitaxel plus gemcitabine and cisplatin in patients with newly diagnosed, advanced biliary tract cancer.